Feasible predictive biomarkers for tumor reaction to mTOR inhibitors, as are described in glioblastoma, breast and prostate cancer cells, often is the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Therefore, this data relies on preclinical assays, determined by in vitro cultured tumor cell strains, which counsel that the e… Read More